Press releases

DexTech receives positive results regarding multiple myeloma

1 February, 2021

DexTech can announce that the company is expanding its preclinical program to also include research into the effect of OsteoDex on multiple myeloma, (MM), in vitro, cell cultures. MM is […]


Interim report July 1 – September 30, 2020

22 October, 2020

By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. First Quarter Summary (July – September 2020) • Net sales amounted to MSEK 0.0 (0.0) • Operating […]


Report from the annual general meeting in DexTech Medical AB on 8 October 2020

8 October, 2020

Today, October 8, 2020, the Annual General Meeting of DexTech Medical AB was held. Below is a summary of the decisions that were made. All decisions were made with the […]


DexTech Medical AB: Invitation to open Annual General Meeting and notice

8 September, 2020

On Thursday, October 8, 2020, DexTech Medical AB (“DexTech”) will hold its Annual General Meeting. Subject to availability, non-shareholders are also welcome to participate without voting rights. At the meeting, […]


Dextech Medical AB Annual report 190701 – 200630

3 September, 2020

Download annual report below. Dextech Annual report 190701-200630


Year-end report July 1, 2019 – June 30, 2020

28 August, 2020

By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. Summary of the Fourth Quarter (April 1 – June 30, 2020) Net sales amounted to MSEK 0,0 […]


DexTech’s Phase IIb study for OsteoDex ends with positive follow-up results

12 June, 2020

The company’s randomized Phase IIb study for the treatment of bone metastatic castration-resistant prostate cancer (mCRPC) has now been completed with 2-year follow-up results from the last patients. The primary […]


DexTech’s Phase IIb study for OsteoDex concludes with positive follow-up results

28 May, 2020

The company’s Phase IIb study for the treatment of skeletal metastatic castration-resistant prostate cancer (mCRPC) shows continued promising follow-up data and confirms previously announced partial results. Formalities in the form […]


Interim report July 1, 2019 – March 31, 2020

6 May, 2020

By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. Summary of the Nine-Month period (2019-07-01 – 2020-03-31)  Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss […]


Half Year report July 1 – December 31, 2019

31 January, 2020

By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. Summary of the First Half Year (2019-07-01 – 2019-12-31) • Net sales amounted to MSEK 0.0 (0.0) […]